Incretin therapy and islet pathology: a time for caution.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis: A meta-analysis.Medicine · 2017
   Pooled it
2. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.Clinical drug investigation · 2015
   Trial
3. Incretin based therapy and pancreatic cancer: Realising the reality.World journal of gastroenterology · 2022
   Review
4. Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine.Acta histochemica et cytochemica · 2019
   Article
5. Effects of Linagliptin on PancreaticJournal of the Endocrine Society · 2017
   Article
6. An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass.Diabetes & metabolism journal · 2016
   Review
7. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015
   Article
8. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.Diabetes, obesity & metabolism · 2014
   Article
9. Extra-pancreatic effects of incretin-based therapies.Endocrine · 2014
   Review
10. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.Diabetes, obesity & metabolism · 2014
    Article
11. Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Journal of diabetes science and technology · 2014
    Article
12. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.Therapeutic advances in drug safety · 2014
    Review
13. Action and therapeutic potential of oxyntomodulin.Molecular metabolism · 2014
    Review
14. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?International journal of clinical practice · 2014
    Review
15. Human β-cell regeneration: progress, hurdles, and controversy.Current opinion in endocrinology, diabetes, and obesity · 2014
    Review
16. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Lancet (London, England) · 2014 · on this map
    Review
17. Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.Diabetes care · 2013
    Article
18. Incretin-based therapies: facing the realities of benefits versus side effects.Diabetes technology & therapeutics · 2013
    Article
19. Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?Diabetologia · 2013
    Article
20. Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus.Clinical medicine insights. Endocrinology and diabetes · 2013
    Review

Corrections and comments

• Comment on
  Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.2013

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as